Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net loss	$ (106,240)	$ (57,762)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation, amortization and accretion	35,918	23,901
Net loss on disposal of property and equipment and impairment expense	8,988	1,311
Share-based compensation	25,048	10,942
Interest expense, related party		1,926
Change in fair value of earnout liability	(3,481)	(2,214)
Change in fair value of warrant liability	(36,157)	(31,105)
Other	67	761
Changes in operating assets and liabilities
Accounts receivable, net	(8,516)	(195)
Receivables from related parties	1,500	(1,425)
Prepaid expenses and other current and noncurrent assets	(2,364)	(5,691)
Operating lease assets and liabilities, net	(519)
Accounts payable	1,371	(1,294)
Payables to related parties		(904)
Accrued liabilities	7,320	7,027
Deferred revenue	13,070	21,925
Customer deposits	6,275	3,931
Other current and noncurrent liabilities	(1,074)	(737)
Net cash used in operating activities	(58,794)	(29,603)
Cash flows from investing activities
Purchases of property, equipment and software	(200,251)	(65,003)
Proceeds from insurance for property losses	710
Purchases of investments	(37,332)
Proceeds from sale of investments	37,166
Acquisition of business, net of cash received		(22,762)
Net cash used in investing activities	(199,707)	(87,765)
Cash flows from financing activities
Issuance of common stock under the ATM	10,654
Capital-build funding, net	10,088	2,909
Proceeds from exercise of warrants	3	30
Proceeds from CRIS Business Combination		601,579
Proceeds from note payable, related party		24,000
Payments on note payable, related party		(5,500)
Payment of transaction costs for CRIS Business Combination		(28,383)
Payments of withholding tax on net issuance of restricted stock units	(25)
Payments of issuance costs and deferred transaction costs	(907)
Net cash provided by financing activities	19,813	594,635
Net (decrease) increase in cash, cash equivalents and restricted cash	(238,688)	477,267
Cash and restricted cash, beginning of period	485,181	7,914
Cash, cash equivalents and restricted cash, end of period	246,493	485,181
Supplemental disclosure of noncash investing and financing activities
Purchases of property and equipment in accounts payable and accrued liabilities	24,422	13,430
Non-cash increase in accounts receivable, capital-build and capital-build liability	8,678	9,272
Non-cash increase in asset retirement obligations	1,822	2,456
Accrued transaction costs	312	352
Reclassification of contingent earnout liability to equity upon triggering event		10,853
Contingent earnout liability recognized upon closing of CRIS Business Combination		18,278
Conversion of note payable, related party, to equity		59,590
Reclassification of redeemable noncontrolling interest on CRIS Close Date		436,739
Fair value adjustment to noncontrolling interest	$ (994,239)	$ 1,525,297